Success Metrics

Active Trials

1(25%)

Phase Distribution

Ph phase_1

75%

Ph phase_3

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

3(75.0%)

Phase 3Large-scale testing

1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Detailed Status

Not yet recruiting3

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 13 (75.0%)

Phase 31 (25.0%)

Trials by Status

recruiting125%

not_yet_recruiting375%

Recent Activity

1 active trials

Showing 4 of 4

not_yet_recruitingphase_3

Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC

NCT07242274

recruitingphase_1

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

NCT06946927

not_yet_recruitingphase_1

To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects

NCT06473948

not_yet_recruitingphase_1

Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects

NCT06348290

Clinical Trials (4)

Showing 4 of 4 trials

NCT07242274Phase 3

Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC

Not Yet Recruiting

NCT06946927Phase 1

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

Recruiting

NCT06473948Phase 1

To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects

Not Yet Recruiting

NCT06348290Phase 1

Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects

Not Yet Recruiting

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4